在肝移植儿科患者中对泰莫西林的群体药理动力学和剂量模拟:一项前性,开放性,非随机化研究
Perrin Ngougni Pokem1, Xavier Stéphenne2, Xin Liu3
1Pharmacologie cellulaire et moléculaire, Louvain Drug Research Institute, Université catholique de Louvain, Brussels, Belgium.
概括
肝移植儿童的泰莫西林剂量需要调整,以获得最佳的有效性. 药理动力学研究表明,目前的治疗方案可能不适合体重较低或功能较高的患者,需要个性化剂量策略.
科学领域:
- 药理学 药理学是指药理学的学科.
- 儿科医学 儿科医学
- 传染性疾病 传染性疾病
背景情况:
- 泰莫西林是一种β-lactam抗生素,用于儿科肝移植患者.
- 细菌感染在这个免疫力低下的人群中是一个重大问题.
- 优化抗生素的药理动力学对于有效的治疗和预防感染至关重要.
研究的目的:
- 在肝移植儿童的血和性液中描述泰莫西林的药理动力学.
- 为这个特定的患者群体提出优化泰莫西林剂量方案.
- 为了最大限度地实现有效的药物暴露,并改善治疗结果.
主要方法:
- 一项药理动力学研究,涉及6至36个月龄的儿科患者,接受两种不同的泰莫西林剂量方案 (25毫克/千克/12小时或25毫克/千克/8小时).
- 测量血和液中总和未结合的泰莫西林度.
- 采用了非分区,人口药理动力学分析和蒙特卡洛模拟.
主要成果:
- 泰莫西林证明了和性蛋白质结合和良好的透到性液体 (中位数为82%).
- 药物动力学概况最好用一个有三个部分的模型来描述,其中体重和估计的GFR作为共变量.
- 蒙特卡洛模拟表明,与25 mg/kg/12h疗法相比,25 mg/kg/8h疗法实现了90%的目标达到的概率,达到更高的MIC和GFR值.
结论:
- 目前的泰莫西林剂量方案可能不足以适用于体重低,功能高或由细菌引起的高最小抑制度 (MIC) 的细菌感染的儿科肝移植患者.
- 针对患者的具体因素对于优化泰莫西林剂量选择至关重要.
- 进一步的儿科药理动力学研究对于完善这种脆弱人群中的抗生素剂量策略至关重要.
相关概念视频
01:21Factors Affecting Drug Response: Overview
1.8K
When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...
1.8K
01:07Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance
26
Drug transporters are critical in drug absorption, distribution, and excretion processes. They should be included in physiological-based pharmacokinetic (PBPK) models, which help predict human drug disposition. However, predicting this is challenging during drug development, especially when liver transport is involved. However, with a realistic representation of body transport processes, an accurate model may be possible.
A recent model describes pravastatin's hepatobiliary excretion,...
A recent model describes pravastatin's hepatobiliary excretion,...
26
01:12Analysis of Population Pharmacokinetic Data
224
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
224
01:19One-Compartment Open Model for IV Bolus Administration: General Considerations
157
The one-compartment model is a pharmacokinetic tool that models the body as a single, uniform compartment, facilitating the understanding of drug distribution and elimination. This model is particularly beneficial for intravenous (IV) bolus administration, where the drug rapidly circulates throughout the body.
The drug's presence in the body is defined by an equation representing the difference between the rates of drug entry and exit. Key parameters—elimination rate constant,...
The drug's presence in the body is defined by an equation representing the difference between the rates of drug entry and exit. Key parameters—elimination rate constant,...
157